Thalassemia clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 12-65
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
Los Angeles, California and other locations
Our lead scientists for Thalassemia research studies include Gary Schiller.